Full-Time

Analyst – Enterprise Risk Management

Posted on 9/11/2025

Deadline 10/31/25
Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

No salary listed

London, UK

Hybrid

Category
Data & Analytics (2)
,
Required Skills
Python
R
SQL
Tableau
Risk Management
Data Analysis
Requirements
  • Minimum of 5 years of experience in operational risk management within the investment management industry, with direct exposure to ERM frameworks, GRC applications, and controls design on technology and data-driven platforms.
  • Demonstrated technical expertise: proficiency with advanced data analytics, data mining, and visualization tools such as SQL, Tableau, PowerBI, and experience with programming languages like Python or R to automate risk reporting and develop actionable dashboards
  • Exceptional communication skills, with the gravitas and presence to engage confidently with senior leaders and risk committees, articulating complex risk concepts in clear, compelling terms.
  • Strong stakeholder management and collaboration abilities, demonstrated by successful cross-functional project delivery and advisory roles across diverse operational teams and geographies.
  • Proven ability to synthesize quantitative and qualitative information and provide strategic, data-driven insights for high-level decision-making.
  • Undergraduate degree required; advanced degree in a quantitative, data science, or risk discipline preferred.
Responsibilities
  • Proactively monitoring the firm’s operational risk profile and controls framework, leveraging advanced data analytics to identify trends, emerging risks, and areas for remediation across governance, process, and technology
  • Designing, developing, and automating regular and ad hoc risk reports and dashboards, utilizing visualization tools and statistical software to clearly communicate complex risk exposures and findings to a range of stakeholders
  • Advising the firm on the development, maintenance, and enhancement of risk and controls registers, including the implementation of data-driven residual risk assessments and the establishment of meaningful risk appetite and key risk indicators (KRIs) in collaboration with other ERM teams
  • Building and maintaining trusted relationships with firmwide peers, collaborating on all matters related to operational risk management, data analytics, and reporting
  • Executing in-depth risk assessment and controls design advisory engagements for top priority risks, integrating quantitative and qualitative data sources to deliver actionable intelligence
  • Implementing and continuously improving the enterprise risk management standards with a focus on data quality, consistency, and transparency
  • Staying abreast of business trends, regulatory changes, and strategic and tactical risks, and using data analytics to anticipate and respond to the evolving risk landscape
  • Preparing comprehensive and insightful reporting and documentation to support risk management and governance forums, ensuring that data-driven insights are a central part of decision-making
  • Responding to critical errors, incidents, or testing results requiring timely remediations, with a focus on data collection, root cause analysis, and lessons learned
  • Testing, deploying, and enhancing the governance, risk, and compliance (GRC) application, with an emphasis on integrating automated data analytics and reporting capabilities
Desired Qualifications
  • Relevant industry certifications (e.g., FRM, PRM, CFA) are highly desirable
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.19T AUM as of December 2024 supports scale across 50 countries.
  • Led Encord's $60M Series C to scale AI data platform in 2026.
  • Private credit market exceeds $30T, fueling 2023-launched capabilities.

What critics are saying

  • BlackRock's $11.5T AUM erodes active fees via ETF scale.
  • Renk's €300M blocked revenue writedowns 5.09% stake value.
  • Quince lawsuit triggers $50-100M liability on Series E investment.

What makes Wellington Management unique

  • Launched Absolute Return Global Equity Fund for market-neutral alpha in volatility.
  • Expanded private real estate credit platform in 2025 with Ravi S. Anand leading.
  • Manages $40B in alternatives across 40 funds for institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE